What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
- Tested for
- Neoplasms, Head and Neck, Neoplasms
- Main trialPhase 2
- “The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).”In the company’s words, NCT06062420 on ClinicalTrials.gov
Other drugs for Neoplasms, Head and Neck
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- BupiZengeOncoZenge AB · Phase 3
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- APG-157Aveta Biomics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 10 Sep 2026 | A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 | |
| Phase 1Active, not recruiting | 30 Jun 2026 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026